drugset / Trial / NCT01821937

Pharmacokinetics of Faldaprevir of Soft Capsule

NCT01821937

Phase 1 Completed 25 enrolled Boehringer Ingelheim
RandomizedParallel-groupOpen-labelTreatment

Summary

The aim of the trial is to assess the bioavailability of Faldaprevir soft capsule with single oral dose and multiple oral doses in Chinese subjects

Timeline

Start
2013-03
Primary completion
2013-05
Completion
2013-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Faldaprevir Small molecule 120 mg Oral
Subject Faldaprevir Small molecule 240 mg Oral

Indications

No indication recorded.